Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 433-439 , March 2010

Extracellular matrix alterations in hypertensive vascular remodeling

  • Catherine A. Lemarié

      Affiliations

    • Lady Davis Institute for Medical Research, McGill University, Montreal, Canada
    • ,
  • Pierre-Louis Tharaux

      Affiliations

    • Paris Cardiovascular Research Center, Inserm U970, HEGP, Paris, France
    • ,
  • Stéphanie Lehoux

      Affiliations

    • Lady Davis Institute for Medical Research, McGill University, Montreal, Canada
    • Paris Cardiovascular Research Center, Inserm U970, HEGP, Paris, France
    • Corresponding Author InformationCorresponding author. Lady Davis Institute for Medical Research, McGill University, 3755 Cote Ste Catherine, Montreal (Qc), Canada H3T 1E2. Tel.: +1 514 340 8222; fax: +1 501 641 8484.

Received 1 August 2009 ,Revised 29 September 2009 ,Accepted 30 September 2009.

References 

  1. Hu JJ, Ambrus A, Fossum TW, Miller MW, Humphrey JD, Wilson E. Time courses of growth and remodeling of porcine aortic media during hypertension: a quantitative immunohistochemical examination. J. Histochem. Cytochem. 2008;56:359–370
  2. O'Rourke MF. Arterial aging: pathophysiological principles. Vasc. Med. 2007;12:329–341
  3. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci. 2002;115:3719–3727
  4. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 2000;1477:267–283
  5. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 1995;77:863–868
  6. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002;90:251–262
  7. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 2005;85:1–31
  8. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 1996;16:28–33
  9. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 2002;91:845–851
  10. Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J. Histochem. Cytochem. 1997;45:837–846
  11. Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation. 2004;109:1041–1047
  12. Jackson ZS, Gotlieb AI, Langille BL. Wall tissue remodeling regulates longitudinal tension in arteries. Circ. Res. 2002;90:918–925
  13. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007;50:212–218
  14. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2438–2448
  15. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006;13:227–231
  16. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J. Hum. Hypertens. 2003;17:119–124
  17. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–540
  18. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003;17:7–30
  19. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 2005;11:867–874
  20. Lemarie CA, Tharaux PL, Esposito B, Tedgui A, Lehoux S. Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries. Circ. Res. 2006;99:434–441
  21. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb. Haemost. 1999;81:799–807
  22. Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, et al. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J. Mol. Cell. Cardiol. 2002;34:617–627
  23. Furumoto T, Fujii S, Nishihara K, Yamada S, Komuro K, Goto K, et al. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1). Am. J. Cardiol. 2004;93:997–1001
  24. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. Faseb J. 2007;21:3029–3041
  25. Fukuda N, Hu WY, Satoh C, Nakayama M, Kishioka H, Kubo A, et al. Contribution of synthetic phenotype on the enhanced angiotensin II-generating system in vascular smooth muscle cells from spontaneously hypertensive rats. J. Hypertens. 1999;17:1099–1107
  26. Galewska Z, Bankowski E, Romanowicz L, Gogiel T, Wolanska M, Jaworski S. Preeclampsia-associated reduction of cathepsin D activity in the umbilical cord. Clin. Chim. Acta. 2005;351:177–184
  27. Platt MO, Ankeny RF, Shi GP, Weiss D, Vega JD, Taylor WR, et al. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2007;292:H1479–1486
  28. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009;119:1785–1794
  29. Lehoux S, Tedgui A. Signal transduction of mechanical stresses in the vascular wall. Hypertension. 1998;32:338–345
  30. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001;81:807–869
  31. Reusch HP, Chan G, Ives HE, Nemenoff RA. Activation of JNK/SAPK and ERK by mechanical strain in vascular smooth muscle cells depends on extracellular matrix composition.. Biochem. Biophys. Res. Commun. 1997;237:239–244
  32. Xu QB, Liu YS, Gorospe M, Udelsman R, Holbrook NJ. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J. Clin. Invest. 1996;97:508–514
  33. Birukov KG, Lehoux S, Birukova AA, Merval R, Tkachuk VA, Tedgui A. Increased pressure induces sustained PKC-independent herbimycin A-sensitive activation of extracellular signal-regulated kinase 1/2 in the rabbit aorta in organ culture. Circ. Res. 1997;81:895–903
  34. Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances Ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J. Biol. Chem. 1997;272:13189–13195
  35. Lehoux S, Esposito B, Merval R, Tedgui A. Differential regulation of vascular focal adhesion kinase by steady stretch and pulsatility. Circulation. 2005;111:643–649
  36. Lehoux S, Esposito B, Merval R, Loufrani L, Tedgui A. Pulsatile stretch-induced extracellular signal-regulated kinase 1/2 activation in organ culture of rabbit aorta involves reactive oxygen species. Arterioscler. Thromb. Vasc. Biol. 2000;20:2366–2372
  37. Lemarie CA, Esposito B, Tedgui A, Lehoux S. Pressure-induced vascular activation of nuclear factor-kappaB: role in cell survival. Circ. Res. 2003;93:207–212
  38. Wang H, Nawata J, Kakudo N, Sugimura K, Suzuki J, Sakuma M, et al. The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo. J. Hypertens. 2004;22:1323–1332
  39. Tschumperlin DJ, Dai G, Maly IV, Kikuchi T, Laiho LH, McVittie AK, et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature. 2004;429:83–86
  40. Shiraya S, Miwa K, Aoki M, Miyake T, Oishi M, Kataoka K, et al. Hypertension accelerated experimental abdominal aortic aneurysm through upregulation of nuclear factor kappaB and Ets. Hypertension. 2006;48:628–636
  41. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension. 2004;44:471–477
  42. Milkiewicz M, Mohammadzadeh F, Ispanovic E, Gee E, Haas TL. Static strain stimulates expression of matrix metalloproteinase-2 and VEGF in microvascular endothelium via JNK- and ERK-dependent pathways. J. Cell. Biochem. 2007;100:750–761
  43. Castier Y, Ramkhelawon B, Riou S, Tedgui A, Lehoux S. Role of NFkappaB in flow-induced vascular remodeling. Antioxid. Redox Signal. 2009;11:1641–1649
  44. Wilkinson IB, McEniery CM. Arterial stiffness, endothelial function and novel pharmacological approaches. Clin. Exp. Pharmacol. Physiol. 2004;31:795–799
  45. Lee HW, Karam J, Hussain B, Winer N. Vascular compliance in hypertension: therapeutic implications. Curr. Diabetes Rep. 2008;8:208–213
  46. Faury G, Pezet M, Knutsen RH, Boyle WA, Heximer SP, McLean SE, et al. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J. Clin. Invest. 2003;112:1419–1428
  47. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490–497
  48. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005;25:932–943
  49. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-equivalents. Matrix Biol. 2003;22:339–350
  50. Marque V, Van Essen H, Struijker-Boudier HA, Atkinson J, Lartaud-Idjouadiene I. Determination of aortic elastic modulus by pulse wave velocity and wall tracking in a rat model of aortic stiffness. J. Vasc. Res. 2001;38:546–550
  51. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003;4:140–156
  52. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int. 2004;65:1790–1794
  53. Mourad JJ, Blacher J, Blin P, Warzocha U. Conventional antihypertensive drug therapy does not prevent the increase of pulse pressure with age. Hypertension. 2001;38:958–961
  54. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ. Res. 2005;97:105–114
  55. Demer LL. A skeleton in the atherosclerosis closet. Circulation. 1995;92:2029–2032
  56. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005;111:2364–2372
  57. Ungvari Z, Csiszar A, Kaminski PM, Wolin MS, Koller A. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am. J. Pathol. 2004;165:219–226
  58. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J. Exp. Med. 2002;196:1047–1055
  59. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  60. Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ. Res. 2008;102:529–537
  61. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241
  62. Stork S, van den Beld AW, von Schacky C, Angermann CE, Lamberts SW, Grobbee DE, et al. Carotid artery plaque burden, stiffness, and mortality risk in elderly men: a prospective, population-based cohort study. Circulation. 2004;110:344–348
  63. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005;111:3384–3390
  64. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–663
  65. London GM. Large arteries haemodynamics: conduit versus cushioning function. Blood Press. Suppl. 1997;2:48–51
  66. Westerhof N, O'Rourke MF. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. J. Hypertens. 1995;13:943–952
  67. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J. Clin. Invest. 2007;117:568–575
  68. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001;59:1834–1841
  69. Schillaci G, Pirro M, Mannarino MR, Pucci G, Savarese G, Franklin SS, et al. Relation between renal function within the normal range and central and peripheral arterial stiffness in hypertension. Hypertension. 2006;48:616–621
  70. Hanon O, Haulon S, Lenoir H, Seux ML, Rigaud AS, Safar M, et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke. 2005;36:2193–2197
  71. Matsumoto M, Inoue K, Moriki A. Associations of brachial-ankle pulse wave velocity and carotid atherosclerotic lesions with silent cerebral lesions. Hypertens. Res. 2007;30:767–773
  72. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment?. Circulation. 2001;104:735–740

PII: S0022-2828(09)00426-X

doi: 10.1016/j.yjmcc.2009.09.018

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 3 , Pages 433-439 , March 2010

Article Tools

* Image Usage & Resolution